Abstract
5-HT and dopamine receptor antagonists have become widely used as atypical antipsychotics. Although 5-HT(2A) receptor antagonistic activity is thought to contribute to the atypical aspects of these agents, the precise mechanism remains unknown. M100907 (R(+)-alpha(2,3-dimethoxyphenyl)-1-[2(4-fluorophenyl)ethyl)]-4-piperidine -methanol), a selective 5-HT(2A) receptor antagonist, is reported to attenuate phencyclidine (PCP)-induced locomotion in rodents. For the purpose of identifying regions in which M100907 exerts its effect, we investigated the effects of M100907 on PCP-induced Fos expression in rat brain. PCP (5 mg/kg, subcutaneously, s.c.) induced Fos expression in the cingulate cortex area 3, the agranular insular cortex, the piriform cortex, the nucleus accumbens, the anterior paraventricular thalamic nucleus and the ventral lateral septal nucleus. Pretreatment with M100907 (0.5 mg/kg, s.c.) attenuated Fos expression induced by PCP in the nucleus accumbens core, the shell, the agranular insular cortex and the piriform cortex. M100907 did not induce Fos expression in any of the regions investigated including the dorsolateral caudate/putamen when given alone. These results indicate that 5-HT(2A) receptor antagonism attenuate...Continue Reading
References
Nov 13, 1992·European Journal of Pharmacology·C J SchmidtV L Taylor
Mar 14, 1991·The New England Journal of Medicine·R J Baldessarini, F R Frankenburg
Aug 15, 1991·The New England Journal of Medicine·L J FriedmanM Sved
May 4, 1990·Neuroscience Letters·Y TaniiK Takahashi
Jan 1, 1988·Life Sciences·L HernandezB G Hoebel
Sep 1, 1989·Journal of Neuroscience Methods·M Dragunow, R Faull
Jan 1, 1989·Psychopharmacology·H Y Meltzer
Jan 1, 1989·Neuroscience·E CarboniG Di Chiara
Oct 8, 1985·European Journal of Pharmacology·E D FrenchR Quirion
Jun 3, 1988·Science·S M SagarT Curran
Feb 29, 1988·Neuroscience Letters·S Y ShuL Z Fan
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Jan 1, 1984·Psychopharmacology·E D French, G Vantini
Feb 1, 1984·Neuropharmacology·W J FreedR J Wyatt
Jul 4, 1995·European Journal of Pharmacology·S Maurel-RemyM J Millan
Apr 1, 1994·Brain Research. Molecular Brain Research·M PompeianoG Mengod
May 28, 1993·Brain Research·R E Steinpreis, J D Salamone
Feb 1, 1995·Clinical Neuropharmacology·T TsutsumiH Uchimura
Jan 1, 1996·Behavioural Brain Research·P C MoserJ H Kehne
Jan 1, 1996·Neuroscience·A Y Deutch, R S Duman
Jan 1, 1996·Behavioural Brain Research·R E Steinpreis
Jan 1, 1997·Psychopharmacology·S D Gleason, H E Shannon
May 30, 1997·Brain Research·J W Sharp
Feb 24, 1998·European Journal of Pharmacology·M A ScheidelerA Fink-Jensen
Apr 18, 1998·Neuroscience Letters·D SatoT Nishikawa
Jun 17, 1999·Pharmacology, Biochemistry, and Behavior·M F O'NeillG Shaw
Jul 23, 1999·Schizophrenia Bulletin·H Y Meltzer, S R McGurk
Dec 14, 1999·The European Journal of Neuroscience·M J MillanS Maurel
Citations
Jul 8, 2005·Psychopharmacology·Charles H LargeDonald C Goff
Dec 6, 2005·Psychopharmacology·C A JenningsE Southam
Jan 30, 2010·Psychopharmacology·Alessandro GozziAngelo Bifone
Sep 3, 2002·Neuroscience and Biobehavioral Reviews·George R BreeseSheryl S Moy
May 15, 2002·Brain Research. Molecular Brain Research·Leo GotohHideyuki Uchimura
Jul 15, 2009·Psychopharmacology·Carolina ChavezMaarten van den Buuse
Sep 24, 2004·Journal of Neurochemistry·Ilaria CegliaRoberto W Invernizzi
Jun 27, 2012·Synapse·Snezana Kusljic, Maarten Van Den Buuse
Jun 15, 2005·Brain Research·Snezana KusljicMaarten van den Buuse
Jun 27, 2014·Frontiers in Neural Circuits·Mirjana Carli, Roberto W Invernizzi
Oct 31, 2016·Neuroscience·Mona E HervigJens D Mikkelsen
Jun 27, 2007·Journal of Psychopharmacology·Charles H Large
May 6, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carli MirjanaClaudia Balducci
Aug 7, 2004·Brain Research. Brain Research Reviews·Teige P SheehanDavid S Russell
Aug 31, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ce Zhang, Gerard J Marek